NCT05677035View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Contraception
Interventions
DRUG

LINO-1713 1 tablet

LINO-1713 1 tablet is administered once. Oral administration with 200mL of water

DRUG

LINO-1713 once a day for 24 days

Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors

Lead Sponsor

Hyundai Pharm
All Listed Sponsors
lead

Hyundai Pharm

INDUSTRY